A number of investment brokers have recently updated their price targets on shares of ANI Pharmaceuticals, Inc. (ANIP). According to the latest broker reports outstanding on Monday 9th of May, 0 analysts have a rating of “strong buy”, 0 analysts “buy”, 0 analysts “neutral”, 0 analysts “sell” and 0 analysts “strong sell”.

Most recent broker ratings

05/05/2016 – ANI Pharmaceuticals, Inc. had its “buy” rating reiterated by analysts at Guggenheim. They now have a USD 55 price target on the stock.

04/13/2016 – ANI Pharmaceuticals, Inc. had its “outperform” rating reiterated by analysts at Oppenheimer. They now have a USD 49 price target on the stock.

11/13/2015 – ANI Pharmaceuticals, Inc. had its “buy” rating reiterated by analysts at Standpoint Research. They now have a USD 54 price target on the stock.

11/04/2015 – ANI Pharmaceuticals, Inc. had its “buy” rating reiterated by analysts at Roth Capital. They now have a USD 56 price target on the stock.

05/11/2015 – ANI Pharmaceuticals, Inc. was downgraded to “sell” by analysts at Zacks.

The share price of ANI Pharmaceuticals, Inc. (ANIP) was down -0.39% during the last day of trading, with a day high of 47.63. 318879 shares were traded during the last session.

The stock’s 50 day moving average is 40.95 and its 200 day moving average is 39.19. The stock’s market capitalization is 532.26M. ANI Pharmaceuticals, Inc. has a 52-week low of 26.80 and a 52-week high of 73.54.

View other investors thoughts on ANI Pharmaceuticals, Inc. with our new Stock Talk discussion platform. Sign up for free to contribute to the community and view research provided from other investors for any stock listed on the LSE, NYSE or NASDAQ.